Streetbeat News

Price Targets

TMO

Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Thermo Fisher Scientific (NYSE:TMO) but lowered the price target from $640 to $600.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:35 pm

PACB

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) and lowered the price target from $13 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:34 pm

OLK

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Olink Holding (NASDAQ:OLK) and raised the price target from $18 to $26.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:33 pm

SQSP

Seaport Global analyst Aaron Kessler has initiated coverage on Squarespace (NYSE:SQSP) with a Buy rating and a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:31 pm

NEO

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on NeoGenomics (NASDAQ:NEO) and lowered the price target from $18 to $16.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:31 pm

NSTG

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on NanoString Technologies (NASDAQ:NSTG) but lowered the price target from $14 to $8.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:29 pm

CTKB

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Cytek Biosciences (NASDAQ:CTKB) but lowered the price target from $13 to $8.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:27 pm

CRL

Morgan Stanley analyst Ricky Goldwasser has maintained an Equal-Weight rating on Charles River (NYSE:CRL) and lowered the price target from $235 to $220.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:23 pm

AA

Morgan Stanley analyst Carlos De Alba has maintained an Underweight rating on Alcoa (NYSE:AA) and lowered the price target from $28.5 to $27.5.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:22 pm

AKYA

Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Akoya Biosciences (NASDAQ:AKYA), but lowered the price target from $15 to $8.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:21 pm